Sveriges mest populära poddar

Research To Practice | Oncology Videos

Hälsa och motion Medicin

Relapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 Review

17 min•13 februari 2026

Featuring an interview with Dr Sagar Lonial, including the following topics:

Phase 3 randomized study evaluating teclistamab and daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib for patients with relapsed/refractory (R/R) multiple myeloma (MM) (0:00)
Management of belantamab mafodotin-associated ocular events with dose modifications guided by standard assessments (3:15)
Belantamab mafodotin in combination with bortezomib, lenalidomide and dexamethasone for transplant-ineligible patients with newly diagnosed MM (8:00)
Other investigational strategies for R/R MM (12:55)

CME information and select publications

Fler avsnitt av Research To Practice | Oncology Videos

Oral SERDs for Breast Cancer | Erica Mayer, MD, MPH, FASCO

30 apr.•29 min

Oral SERDs for Breast Cancer | Aditya Bardia, MD, MPH

30 apr.•28 min

EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances

27 apr.•57 min

EGFR-Mutant Non-Small Cell Lung Cancer | Suresh S Ramalingam, MD

27 apr.•26 min

EGFR-Mutant Non-Small Cell Lung Cancer | Helena Yu, MD

27 apr.•30 min

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium

25 apr.•17 min

Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances

23 apr.•58 min

Prostate Cancer | Scott T Tagawa, MD, MS

23 apr.•25 min

Prostate Cancer | Andrew J Armstrong, MD, ScM

23 apr.•24 min

Menin Inhibitors in Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances

20 apr.•59 min

Research To Practice | Oncology Videos med Dr Neil Love finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.